Wealth Enhancement Advisory Services LLC Cuts Stock Holdings in Apyx Medical Co. (NASDAQ:APYX)

Wealth Enhancement Advisory Services LLC lessened its position in Apyx Medical Co. (NASDAQ:APYX) by 42.5% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 90,798 shares of the company’s stock after selling 67,148 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Apyx Medical were worth $113,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in APYX. Private Advisor Group LLC raised its stake in Apyx Medical by 3.9% in the 3rd quarter. Private Advisor Group LLC now owns 322,321 shares of the company’s stock valued at $400,000 after purchasing an additional 12,180 shares during the last quarter. RPg Family Wealth Advisory LLC purchased a new stake in shares of Apyx Medical during the second quarter worth $101,000. Rathbones Group PLC grew its holdings in shares of Apyx Medical by 148.0% during the second quarter. Rathbones Group PLC now owns 251,334 shares of the company’s stock worth $337,000 after buying an additional 150,000 shares in the last quarter. Commonwealth Equity Services LLC raised its position in shares of Apyx Medical by 2.9% in the second quarter. Commonwealth Equity Services LLC now owns 511,561 shares of the company’s stock valued at $685,000 after buying an additional 14,481 shares during the last quarter. Finally, Perkins Capital Management Inc. lifted its stake in shares of Apyx Medical by 7.0% in the first quarter. Perkins Capital Management Inc. now owns 228,500 shares of the company’s stock worth $311,000 after buying an additional 15,000 shares in the last quarter. Hedge funds and other institutional investors own 55.33% of the company’s stock.

Apyx Medical Trading Down 7.4 %

Shares of APYX opened at $1.37 on Wednesday. Apyx Medical Co. has a 12-month low of $0.97 and a 12-month high of $3.26. The firm has a market capitalization of $47.46 million, a P/E ratio of -1.65 and a beta of 1.21. The firm has a 50-day moving average price of $1.21 and a 200 day moving average price of $1.33. The company has a current ratio of 5.33, a quick ratio of 4.45 and a debt-to-equity ratio of 2.26.

Apyx Medical (NASDAQ:APYX) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. The business had revenue of $11.49 million during the quarter, compared to analysts’ expectations of $11.66 million. Apyx Medical had a negative net margin of 57.86% and a negative return on equity of 105.45%. During the same quarter in the prior year, the company posted ($0.13) EPS. Sell-side analysts forecast that Apyx Medical Co. will post -0.7 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. BTIG Research assumed coverage on shares of Apyx Medical in a research note on Thursday, October 17th. They set a “neutral” rating for the company. Craig Hallum raised Apyx Medical to a “strong-buy” rating in a report on Thursday, October 24th. Finally, JMP Securities reissued a “market perform” rating on shares of Apyx Medical in a research note on Monday, September 16th.

Apyx Medical Profile

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.